EOD-3
Retinal Surgery (Tamponade)
PreclinicalActive
Key Facts
About Avant Sciences
Avant Sciences is a private, preclinical-stage biotech focused on revolutionizing retinal surgery through its proprietary evaporative tamponade platform. The company's lead program, evapRET, is in GMP production and in vivo pre-IDE testing, with three other pipeline candidates (EOD-2, EOD-3, EOD-4) in various stages of preclinical development. Led by a clinician-founder with deep expertise in vitreoretinal surgery and supported by a seasoned team of ophthalmology experts, the company is advancing towards regulatory milestones while presenting data at major medical conferences. Avant Sciences is currently pre-revenue and appears to be funded by a seed round closed in September 2023.
View full company profileTherapeutic Areas
Other Retinal Surgery (Tamponade) Drugs
| Drug | Company | Phase |
|---|---|---|
| evapRET | Avant Sciences | Preclinical |
| EOD-2 | Avant Sciences | Preclinical |
| EOD-4 | Avant Sciences | Preclinical |